Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.
Friedman CF, Manning-Geist BL, Zhou Q, Soumerai T, Holland A, Da Cruz Paula A, Green H, Ozsoy MA, Iasonos A, Hollmann T, Leitao MM Jr, Mueller JJ, Makker V, Tew WP, O'Cearbhaill RE, Liu YL, Rubinstein MM, Troso-Sandoval T, Lichtman SM, Schram A, Kyi C, Grisham RN, Causa Andrieu P, Wherry EJ, Aghajanian C, Weigelt B, Hensley ML, Zamarin D. Friedman CF, et al. Among authors: rubinstein mm. Nat Med. 2024 May;30(5):1330-1338. doi: 10.1038/s41591-024-02942-7. Epub 2024 Apr 23. Nat Med. 2024. PMID: 38653864 Free PMC article. Clinical Trial.
Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
Stasenko M, Tunnage I, Ashley CW, Rubinstein MM, Latham AJ, Da Cruz Paula A, Mueller JJ, Leitao MM Jr, Friedman CF, Makker V, Soslow RA, DeLair DF, Hyman DM, Zamarin D, Alektiar KM, Aghajanian CA, Abu-Rustum NR, Weigelt B, Cadoo KA. Stasenko M, et al. Among authors: rubinstein mm. Gynecol Oncol. 2020 Jan;156(1):194-202. doi: 10.1016/j.ygyno.2019.10.028. Epub 2019 Nov 19. Gynecol Oncol. 2020. PMID: 31757464 Free PMC article.
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Rubinstein MM, Hyman DM, Caird I, Won H, Soldan K, Seier K, Iasonos A, Tew WP, O'Cearbhaill RE, Grisham RN, Hensley ML, Troso-Sandoval T, Sabbatini P, Guillen J, Selcuklu SD, Zimel C, Torrisi J, Aghajanian C, Makker V. Rubinstein MM, et al. Cancer. 2020 Mar 15;126(6):1274-1282. doi: 10.1002/cncr.32677. Epub 2019 Dec 27. Cancer. 2020. PMID: 31880826 Free PMC article. Clinical Trial.
A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers.
Rubinstein MM, Grisham RN, Cadoo K, Kyi C, Tew WP, Friedman CF, O'Cearbhaill RE, Zamarin D, Zhou Q, Iasonos A, Nikolovski I, Xu H, Soldan KN, Caird I, Martin M, Guillen J, Eid KT, Aghajanian C, Makker V. Rubinstein MM, et al. Gynecol Oncol. 2021 Jan;160(1):71-76. doi: 10.1016/j.ygyno.2020.10.019. Epub 2020 Nov 1. Gynecol Oncol. 2021. PMID: 33139041 Free PMC article. Clinical Trial.
Microsatellite Instability-High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles.
Manning-Geist BL, Liu YL, Devereaux KA, Paula ADC, Zhou QC, Ma W, Selenica P, Ceyhan-Birsoy O, Moukarzel LA, Hoang T, Gordhandas S, Rubinstein MM, Friedman CF, Aghajanian C, Abu-Rustum NR, Stadler ZK, Reis-Filho JS, Iasonos A, Zamarin D, Ellenson LH, Lakhman Y, Mandelker DL, Weigelt B. Manning-Geist BL, et al. Among authors: rubinstein mm. Clin Cancer Res. 2022 Oct 3;28(19):4302-4311. doi: 10.1158/1078-0432.CCR-22-0713. Clin Cancer Res. 2022. PMID: 35849120 Free PMC article.
Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservation.
Manning-Geist B, Gordhandas S, Hodgson A, Zhou QC, Iasonos A, Chi DS, Ellenson L, Aghajanian CA, Abu-Rustum NR, Leitao M, Long K, Rubinstein MM, Sonoda Y, Alektiar K, Weigelt B, Zivanovic O, Grisham RN. Manning-Geist B, et al. Among authors: rubinstein mm. Int J Gynecol Cancer. 2022 Dec 5;32(12):1576-1582. doi: 10.1136/ijgc-2022-003935. Int J Gynecol Cancer. 2022. PMID: 36368707 Free PMC article.
Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study.
Rubinstein MM, Doria ER, Konner J, Lichtman S, Zhou Q, Iasonos A, Sarasohn D, Troso-Sandoval T, Friedman C, O'Cearbhaill R, Cadoo K, Kyi C, Cohen S, Soldan K, Billinson E, Caird I, Jang D, Eid K, Shah P, Guillen J, Aghajanian C, Zamarin D, Makker V. Rubinstein MM, et al. Gynecol Oncol. 2023 Feb;169:64-69. doi: 10.1016/j.ygyno.2022.11.028. Epub 2022 Dec 10. Gynecol Oncol. 2023. PMID: 36512912 Free PMC article. Clinical Trial.
Germline drivers of gynecologic carcinosarcomas.
Sia TY, Gordhandas SB, Birsoy O, Kemel Y, Maio A, Salo-Mullen E, Sheehan M, Hensley ML, Rubinstein M, Makker V, Grisham RN, O'Cearbhaill RE, Roche KL, Mueller JJ, Leitao MM Jr, Sonoda Y, Chi DS, Abu-Rustum NR, Berger MF, Ellenson LH, Latham A, Stadler Z, Offit K, Aghajanian C, Weigelt B, Mandelker D, Liu YL. Sia TY, et al. Among authors: rubinstein m. Gynecol Oncol. 2023 Jul;174:34-41. doi: 10.1016/j.ygyno.2023.04.024. Epub 2023 May 5. Gynecol Oncol. 2023. PMID: 37149903
21 results